首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 7期 妊娠期肝病的个体化精准诊疗 => 肝脏肿瘤 =>超液态碘化油联合药物..
超液态碘化油联合药物洗脱微球经肝动脉化疗栓塞术治疗巴塞罗那B/C期肝细胞癌的效果分析
Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma
文章发布日期:2019年06月14日  来源:  作者:唐浩桓,朱晓黎,王万胜,等  点击次数:242次  下载次数:49次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的研究超液态碘化油联合药物洗脱微球经动脉化疗栓塞术(TACE)治疗巴塞罗那(BCLC)B/C期肝细胞癌(HCC)的有效性和安全性。方法回顾性分析2016年5月-2018年9月苏州大学附属第一医院接受超液态碘化油联合药物洗脱微球栓塞治疗的51例BCLC B/C期HCC患者,比较治疗前和治疗后3 d、7 d、1个月的肝功能变化,详细记录不良反应及并发症发生情况,采用改良实体瘤疗效评价标准(mRECIST)评价术后1、3个月临床疗效。计量资料组间比较采用t检验。结果51例患者均完成超选择栓塞,治疗病灶术后1个月疾病缓解率为70.6%,疾病控制率为96.1%;3个月疾病缓解率为64.0%,疾病控制率为88.0%。术后3 d急性肝损伤发生率9.8%(5/51),ALT、AST、TBil、Alb变化较术前有明显差异(t值分别为-5.454、-3.997、-5.346、7212,P值均<0.001),术后1周ALT、TBil、Alb变化较术前有明显差异(t值分别为-3.177、-3.665、3.194,P值均<0.05)。术后1个月1级和2级不良反应发生率为68.6%(35/51),未出现肝衰竭、肝脓肿、胆汁瘤、消化道出血等并发症,1例患者术后61 d因肿瘤进展死于多脏器功能衰竭。结论超液态碘化油联合药物洗脱微球TACE治疗BCLC B/C期HCC是安全有效的,远期疗效及生存获益有待于进一步观察。
【Abstract】:ObjectiveTo investigate the clinical effect and safety of transarterial chemoembolization (TACE) with ultra-liquid iodized oil combined with drug-eluting beads in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for the clinical data of 51 patients with BCLC stage B/C HCC who underwent TACE with ultra-liquid iodized oil combined with drug-eluting beads in The First Affiliated Hospital of Soochow University from May 2016 to September 2018. Liver function was observed before treatment and at 3 days, 7 days, and 1 month after treatment, and adverse events and complications were recorded in detail. Modified Response Evaluation Criteria in Solid Tumors was used to evaluate clinical outcome at 1 and 3 months after surgery. The t-test was used for comparison of continuous data between two groups. ResultsSuperselective TACE procedure was completed in all 51 patients. At 1 month after surgery, the target lesions had a disease remission rate of 70.6% and a disease control rate of 96.1%, while at 3 months after surgery, the target lesions had a disease remission rate of 64.0% and a disease control rate of 880%. Of all 51 patients, 5 (9.8%) experienced acute liver injury at 3 days after surgery, and there were significant changes in alanine aminotransferase (ALT), aspartate aminotransferase, total bilirubin (TBil), and albumin (Alb) (t=-5.454, -3.997, -5.346, and 7212, all P<0.001). There were also significant changes in ALT, TBil, and Alb at 7 days after surgery (t=-3.177, -3.665, and 3194, all P<0.05). Of all 51 patients, 35 (68.6%) experienced grade 1 or 2 adverse events at 1 month after surgery, and no complications of liver failure, liver abscess, bile tumor, and gastrointestinal bleeding were observed. One patient died of multiple organ failure due to tumor progression on day 61 after surgery. ConclusionTACE with ultra-liquid iodized oil combined with drug-eluting beads is safe and effective in the treatment of BCLC stage B/C HCC, and further studies are needed to observe long-term efficacy and survival benefit.
【关键字】:癌, 肝细胞;碘化油;微球体;化学栓塞, 治疗性
【Key words】:carcinoma, hepatocellular; iodized oil; microspheres; chemoembolization, therapeutic
【引证本文】:TANG HH, ZHU XL, WANG WS, et al. Clinical effect of transarterial chemoembolization with ultra-liquid iodized oil combined with drug-eluting beads in treatment of Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(7): 1509-1513. (in Chinese)
唐浩桓,朱晓黎,王万胜,等. 超液态碘化油联合药物洗脱微球经肝动脉化疗栓塞术治疗巴塞罗那B/C期肝细胞癌的效果分析[J]. 临床肝胆病杂志, 2019, 35(7): 1509-1513.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号